Today: 22 May 2026
Netflix stock at $86: ‘Sniff test’ jab keeps NFLX in play before Monday
25 January 2026
2 mins read

Netflix stock at $86: ‘Sniff test’ jab keeps NFLX in play before Monday

New York, Jan 25, 2026, 10:54 (ET) — Market closed.

Netflix shares closed Friday up 3.1% at $86.12, after fluctuating between $83.35 and $86.30. Investors remain focused on Netflix’s ongoing bid for Warner Bros Discovery. Co-CEO Greg Peters dismissed Paramount Skydance’s competing offer as one that “doesn’t pass the sniff test,” according to the Financial Times. Reuters

U.S. markets are closed for the weekend, but Netflix is entering Monday trading as much a deal play as a media stock. The potential Warner merger now dominates the story — hinging on price, financing, and whether regulators choose to intervene.

This matters because the deal now hinges not just on subscriber growth and fresh content. It’s also about Netflix’s ability to maintain a flexible balance sheet while shelling out cash for a studio-heavy acquisition amid a political and regulatory environment increasingly hostile to big mergers.

On Jan. 20, Netflix and Warner announced they’d revised their deal into an all-cash transaction worth $27.75 per Warner share. Warner also filed a preliminary proxy statement with the U.S. SEC. The new arrangement aims to let Warner shareholders cast their votes by April.

Netflix has switched from a combination of cash and its own shares to an all-cash offer, keeping the headline price at $82.7 billion. This move removes stock-market fluctuations from the valuation. “A cash bid strips away uncertainty,” said Matt Britzman, senior equity analyst at Hargreaves Lansdown, though he cautioned that the change doesn’t resolve the antitrust concerns. Reuters

Netflix reported in its Jan. 20 quarterly shareholder letter that fourth-quarter revenue climbed to $12.051 billion, with diluted earnings per share hitting $0.56 after its 10-for-1 stock split. The company projects full-year 2026 revenue between $50.7 billion and $51.7 billion, anticipating advertising revenue to nearly double. Its revenue forecast for the first quarter stands at $12.157 billion.

The deal is already impacting capital returns and funding choices. Netflix halted share buybacks to conserve cash for the Warner acquisition. It secured commitments for a $59 billion bridge loan, which was later upped by $8.2 billion, and disclosed roughly $60 million in costs related to arranging that financing, according to a Reuters report.

Since Netflix rolled out its Warner strategy in early December, the stock has been all over the place. Reuters noted the shares dropped roughly 20% from that time, as investors balanced concerns over deal risks with otherwise strong operational progress.

The drop in share price also stems from a mechanical shift. Netflix completed a 10-for-1 forward stock split in November, set to start trading on a split-adjusted basis on Nov. 17, following board approval in late October, according to a company statement.

Macro forces could still take the lead. The Federal Reserve’s upcoming policy meeting is set for Jan. 27–28, a date that often rattles rate-sensitive growth stocks, even absent fresh company updates.

The biggest risk still lies with the deal itself. According to Reuters, EU antitrust regulators plan to examine the competing Netflix and Paramount bids on a similar schedule. This raises the likelihood of an extended review, approval conditions, or a clearance process that could favor one bidder over the other.

Investors will be eyeing the ticking clock this week as Paramount Skydance pushed back the deadline for its hostile tender offer for Warner to Feb. 20. So far, just 6.8% of Warner’s outstanding shares were tendered by the original cutoff, according to Reuters.

Stock Market Today

  • Keros Therapeutics (KROS) Advances Rinvatercept for DMD, ALS in 2026
    May 22, 2026, 12:45 PM EDT. Keros Therapeutics (KROS) is advancing rinvatercept, its lead neuromuscular drug candidate targeting transforming growth factor-beta ligands to treat Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The FDA granted orphan drug designation for rinvatercept in August 2025, underscoring regulatory progress. The company aims to start a Phase II trial in DMD patients by Q3 2026. Rinvatercept seeks to inhibit muscle-degrading proteins to promote muscle regeneration, reduce fibrosis, and enhance bone strength. Keros's focus on this pathway targets unmet needs in DMD treatment, potentially offering an alternative to corticosteroids, which can cause muscle breakdown and fat gain. The company has streamlined its R&D after transferring elritercept costs to Takeda, concentrating resources on rinvatercept development. Multiple upcoming clinical and regulatory milestones could shift investor expectations in 2026.

Latest articles

Ondas Stock Looks to Next Move After $196.6M AI-Defense Agreement

Ondas Stock Looks to Next Move After $196.6M AI-Defense Agreement

22 May 2026
Ondas shares rose 0.54% to $9.23 in New York Friday after closing its $196.6 million stock acquisition of Israel’s Omnisys on May 21. The company also filed to register the resale of 2.7 million shares tied to a separate Mistral deal. U.S. markets will close Monday for Memorial Day, leaving one session for investors to react. Ondas’ market value stood at $4.57 billion, well below its 52-week high.
HP Up 15% Before Earnings, Wall Street Warns on Rally

HP Up 15% Before Earnings, Wall Street Warns on Rally

22 May 2026
HP Inc. shares surged 15.5% to $25.29 by midday Friday, outpacing the S&P 500 and Nasdaq ahead of its May 27 earnings report. Dell Technologies and Hewlett Packard Enterprise also posted strong gains. Analysts remain divided, with Bank of America maintaining a Sell rating and JPMorgan raising its target to $22, still below HP’s current price. Interim CEO Bruce Broussard leads HP after Enrique Lores stepped down in February.
PicoCELA Jumps Over 100% with Nasdaq Float Draws In Traders

PicoCELA Jumps Over 100% with Nasdaq Float Draws In Traders

22 May 2026
PicoCELA’s U.S.-listed shares surged 141% to $5.43 by midday Friday, with trading volume topping 22 million shares. The spike followed a 60.7% jump Thursday and came despite no new operating news. Shareholders are set to vote May 30 on expanding a Class A preferred share allotment. The company’s float is about 1.08 million shares, according to TipRanks.
Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next
Previous Story

Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing
Next Story

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing

Go toTop